Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States of America.
Medical Writing and Publications, Ironwood Pharmaceuticals, Inc., Boston, MA, United States of America.
PLoS One. 2021 Jan 11;16(1):e0243318. doi: 10.1371/journal.pone.0243318. eCollection 2021.
Chronic idiopathic constipation (CIC) is a prevalent functional gastrointestinal disorder diagnosed based on patient-reported symptoms and the absence of structural gastrointestinal abnormalities. Individuals with CIC typically institute dietary changes and use stool softeners or over-the-counter (OTC) laxatives, possibly at the direction of a healthcare provider, before prescription medications for CIC are initiated. Although highly prevalent, there is limited information regarding CIC patient experiences with OTC medications.
This post-hoc analysis used patient-reported data from a questionnaire administered during patient screening for a prospective linaclotide Phase 3b clinical trial in patients with CIC (N = 1482 screened). The questionnaire asked patients to report their experiences with OTC CIC medications over the preceding 6 months.
Among patients with screening responses (N = 1423), most were female (85%) and white (66%), with a mean age of 48.9 years. A high proportion of patients had used one or more OTC medications (70% had ≥1 OTC; 19% had ≥3 OTCs), with the majority being bisacodyl (33%) and polyethylene glycol (30%). The most commonly cited reason for stopping an OTC medication was insufficient symptom relief (17-40%). The majority of patients taking OTC medications reported no or little satisfaction with the medication's effect on their constipation (62%) and CIC-specific abdominal symptoms (78%). Many patients had little to no confidence in bowel movement (BM) frequency after taking OTC medications and their confidence in their ability to predict BM timing was also low (49-81% not at all confident).
Treatment effects on individual CIC symptoms, predictability of bowel habits, and satisfaction with treatment are all important factors for healthcare providers and patients to consider when establishing an effective treatment regimen for CIC.
NCT01642914.
慢性特发性便秘(CIC)是一种常见的功能性胃肠道疾病,根据患者报告的症状和缺乏结构胃肠道异常来诊断。CIC 患者通常会在开始使用 CIC 的处方药之前,自行改变饮食、使用大便软化剂或非处方(OTC)泻药,可能会在医疗保健提供者的指导下进行。尽管 CIC 非常普遍,但关于 CIC 患者使用 OTC 药物的经验的信息有限。
本事后分析使用了来自 CIC 患者前瞻性利那洛肽 3b 期临床试验筛选期间问卷调查的患者报告数据(N = 1482 名筛选)。该问卷要求患者报告过去 6 个月中使用 OTC CIC 药物的经历。
在有筛选回复的患者中(N = 1423),大多数为女性(85%)和白人(66%),平均年龄为 48.9 岁。高比例的患者使用了一种或多种 OTC 药物(70%使用了≥1 种 OTC;19%使用了≥3 种 OTC),其中大多数是比沙可啶(33%)和聚乙二醇(30%)。停止 OTC 药物的最常见原因是症状缓解不足(17-40%)。大多数服用 OTC 药物的患者报告对药物治疗便秘(62%)和 CIC 特定腹部症状(78%)的效果不满意或几乎不满意。许多患者对服用 OTC 药物后排便(BM)频率几乎没有信心,对预测 BM 时间的信心也很低(49-81%完全没有信心)。
治疗对 CIC 特定症状的效果、排便习惯的可预测性以及对治疗的满意度,都是医疗保健提供者和患者在为 CIC 制定有效治疗方案时需要考虑的重要因素。
NCT01642914。